.38-41 seems to be the floor for the stock. Their financing methods (LPC/Convertibles) will hold the share price back. I don't think we'll see $1 for a long time.

The CMS reimbursement rate is almost exactly where they priced treatment. The leading product in this space is Shire Pharmaceutical's Dermagraft, it doesn't work and cost 3x as much. The second most popular is Apligraft which falls in-between Dermagraft and Autologel in effectiveness but stillcosts $1000-1200 per treatment.

I don't own enough CMXI to be an expert but they do have a considerable pricing and effectiveness advantage over the competition. Also, Shire is dismantling their R&D division (despite it being profitable) and will now be even more focused on acquisitions. Cytomedix may be on their radar.